240 related articles for article (PubMed ID: 29719429)
1. Prescribing practices of endocrine therapy for ductal carcinoma
Chaudhry AT; Koulis TA; Speers C; Olson RA
Curr Oncol; 2018 Apr; 25(2):133-138. PubMed ID: 29719429
[TBL] [Abstract][Full Text] [Related]
2. Trends in adjuvant therapies after breast-conserving surgery for hormone receptor-positive ductal carcinoma in situ: findings from the National Cancer Database, 2004-2013.
Sagara Y; Freedman RA; Wong SM; Aydogan F; Nguyen A; Barry WT; Golshan M
Breast Cancer Res Treat; 2017 Nov; 166(2):583-592. PubMed ID: 28776282
[TBL] [Abstract][Full Text] [Related]
3. Factors Influencing Use of Hormone Therapy for Ductal Carcinoma In Situ: A National Cancer Database Study.
Nguyen TT; Hoskin TL; Day CN; Habermann EB; Goetz MP; Boughey JC
Ann Surg Oncol; 2017 Oct; 24(10):2989-2998. PubMed ID: 28766214
[TBL] [Abstract][Full Text] [Related]
4. Population-based analysis of the impact and generalizability of the NSABP-B24 study on endocrine therapy for patients with ductal carcinoma in situ of the breast.
Lo AC; Truong PT; Wai ES; Nichol A; Weir L; Speers C; Hayes MM; Baliski C; Tyldesley S
Ann Oncol; 2015 Sep; 26(9):1898-1903. PubMed ID: 26063632
[TBL] [Abstract][Full Text] [Related]
5. Trends in Treatment Patterns and Outcomes for Ductal Carcinoma In Situ.
Worni M; Akushevich I; Greenup R; Sarma D; Ryser MD; Myers ER; Hwang ES
J Natl Cancer Inst; 2015 Dec; 107(12):djv263. PubMed ID: 26424776
[TBL] [Abstract][Full Text] [Related]
6. Ductal carcinoma in situ, complexities and challenges.
Leonard GD; Swain SM
J Natl Cancer Inst; 2004 Jun; 96(12):906-20. PubMed ID: 15199110
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24.
Allred DC; Anderson SJ; Paik S; Wickerham DL; Nagtegaal ID; Swain SM; Mamounas EP; Julian TB; Geyer CE; Costantino JP; Land SR; Wolmark N
J Clin Oncol; 2012 Apr; 30(12):1268-73. PubMed ID: 22393101
[TBL] [Abstract][Full Text] [Related]
8. Variations in treatment for ductal carcinoma in situ in elderly women.
Gold HT; Dick AW
Med Care; 2004 Mar; 42(3):267-75. PubMed ID: 15076826
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant Endocrine Therapy in Patients with Ductal Carcinoma In Situ: A Population-Based Retrospective Analysis from 2005 to 2012 in the National Cancer Data Base.
Flanagan MR; Rendi MH; Gadi VK; Calhoun KE; Gow KW; Javid SH
Ann Surg Oncol; 2015 Oct; 22(10):3264-72. PubMed ID: 26202556
[TBL] [Abstract][Full Text] [Related]
10. Tamoxifen Initiation After Ductal Carcinoma In Situ.
Nichols HB; Bowles EJ; Islam J; Madziwa L; Stürmer T; Tran DT; Buist DS
Oncologist; 2016 Feb; 21(2):134-40. PubMed ID: 26768485
[TBL] [Abstract][Full Text] [Related]
11. Delay in radiotherapy is associated with an increased risk of disease recurrence in women with ductal carcinoma in situ.
Shurell E; Olcese C; Patil S; McCormick B; Van Zee KJ; Pilewskie ML
Cancer; 2018 Jan; 124(1):46-54. PubMed ID: 28960259
[TBL] [Abstract][Full Text] [Related]
12. Genomic Assays in Ductal Carcinoma In Situ: Implications for Management Decisions.
Gangi A; Topham A; Lee MC; Sun W; Laronga C
South Med J; 2017 Oct; 110(10):649-653. PubMed ID: 28973706
[TBL] [Abstract][Full Text] [Related]
13. Endocrine Therapy Initiation and Medical Oncologist Utilization Among Women Diagnosed with Ductal Carcinoma in Situ.
Anderson C; Meyer AM; Wheeler SB; Zhou L; Reeder-Hayes KE; Nichols HB
Oncologist; 2017 May; 22(5):535-541. PubMed ID: 28408621
[TBL] [Abstract][Full Text] [Related]
14. Ductal Carcinoma in Situ: A French National Survey. Analysis of 2125 Patients.
Cutuli B; Lemanski C; De Lafontan B; Chauvet MP; De Lara CT; Mege A; Fric D; Richard-Molard M; Mazouni C; Cuvier C; Carre A; Kirova Y
Clin Breast Cancer; 2020 Apr; 20(2):e164-e172. PubMed ID: 31780381
[TBL] [Abstract][Full Text] [Related]
15. Impact of CALGB 9343 Trial and Sociodemographic Variation on Patterns of Adjuvant Radiation Therapy Practice for Elderly Women (≥70 Years) with Stage I, Estrogen Receptor-positive Breast Cancer: Analysis of the National Cancer Data Base.
Chu QD; Zhou M; Medeiros KL; Peddi P; Wu XC
Anticancer Res; 2017 Oct; 37(10):5585-5594. PubMed ID: 28982874
[TBL] [Abstract][Full Text] [Related]
16. Multidisciplinary Shared Decision Making in the Management of Ductal Carcinoma In Situ of the Breast.
Parikh P; Pockaj B; Wasif N; Halyard M; Wong W; Kosiorek HE; Dueck AC; Gray R
Ann Surg Oncol; 2015 Dec; 22 Suppl 3(0 3):S516-21. PubMed ID: 25986869
[TBL] [Abstract][Full Text] [Related]
17. Benefit of low-dose tamoxifen in a large observational cohort of high risk ER positive breast DCIS.
Guerrieri-Gonzaga A; Sestak I; Lazzeroni M; Serrano D; Rotmensz N; Cazzaniga M; Varricchio C; Pruneri G; Leonardi MC; Orecchia R; Galimberti V; Bonanni B; DeCensi A
Int J Cancer; 2016 Nov; 139(9):2127-34. PubMed ID: 27381855
[TBL] [Abstract][Full Text] [Related]
18. Breast-Conserving Surgery in Patients With Mammary Paget's Disease.
Yao Y; Sun L; Meng Y; Zhuang Y; Zhao L; Yu Q; Si C
J Surg Res; 2019 Sep; 241():178-187. PubMed ID: 31026796
[TBL] [Abstract][Full Text] [Related]
19. Variation in the management of ductal carcinoma in situ in the UK: Results of the Mammary Fold National Practice Survey.
Mammary Fold Academic and Research Collaborative
Eur J Surg Oncol; 2016 Aug; 42(8):1153-61. PubMed ID: 27344543
[TBL] [Abstract][Full Text] [Related]
20. Patterns of care analysis among women with ductal carcinoma in situ in North Carolina.
Jackson LC; Camacho F; Levine EA; Anderson RT; Stewart JH
Am J Surg; 2008 Feb; 195(2):164-9. PubMed ID: 18096124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
